|
Carcinoma of lung
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Carcinoma of lung
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
The PIK3CA copy number increase was validated using fluorescence in situ hybridization to lung cancer tissue microarrays.
|
12097266 |
2002 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Cotransfection of the constitutively active mutant Rac-1 (Val12), an upstream activator of JNK, abrogated Deltap85-induced lung cancer cell death, whereas constitutively active mutant mitogen-activated protein kinase kinase (MKK)-1 (R4F) did not.
|
12714585 |
2003 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, the clinico-pathological background for PIK3CA gene mutations has not yet been investigated in lung cancer.
|
16930767 |
2006 |
|
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
|
17409929 |
2006 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutation and amplification in human lung cancer.
|
17803655 |
2007 |
|
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
|
17992665 |
2008 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.
|
19394761 |
2009 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
This finding set the stage for further testing of FLJ10540 as a new therapeutic target for treating lung cancer and may contribute to the development of new therapeutic strategies that are able to block the PI3K/AKT pathway in lung cancer cells.
|
19337377 |
2009 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Activation to a large extent of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and mutations in the p53 gene are involved in lung cancer therapeutic resistance.
|
20811722 |
2010 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our work further suggests that additional lung cancer chemoprevention trials either targeting the PI3K pathway or measuring airway PI3K activation as an intermediate endpoint are warranted.
|
20375364 |
2010 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
cIAP2 upregulated by E6 via EGFR/PI3K/AKT cascades may contribute to cisplatin resistance, revealing that the EGFR or PI3K inhibitor combined with cisplatin may improve the chemotherapeutic efficacy in HPV-infected lung cancer.
|
20959404 |
2010 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Furthermore, possible interplay between PI3K/Akt/mTOR pathway activation/inhibition and RhoGDI2 signalling is examined in lung cancer-related cell lines.
|
20596634 |
2010 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
The increased TxA(2) may then activate CREB through PI3K/Akt and extracellular ERK pathways, thereby contributing to the NNK-promoted survival and growth of lung cancer cells.
|
20818420 |
2011 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
|
21220474 |
2011 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway.
|
21861134 |
2011 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways.
|
21688263 |
2012 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Aberrant activation of PI3K/AKT signalling represents one of the most common molecular alterations in lung cancer, though the relative contribution of the single components of the cascade to the NSCLC development is still poorly defined.
|
22363436 |
2012 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer.
|
21996732 |
2012 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Moreover, previous studies have shown that Pg extracts decrease inflammation in lung cancer cell lines by inhibiting phosphatidylinositol-3,4,5-trisphosphate (PI3K)-dependent phosphorylation of AKT in vitro and inhibiting the activation of NF-kB in vivo.
|
22941571 |
2012 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinositide 3-kinase)/PDK1 (3-phosphoinositide-dependent protein kinase)/Akt that determines receptor signal selectivity for non-mutated EGFR, and assessed its role in EGFR mutant lung cancer with or without gatekeeper T790M mutation.
|
23045273 |
2013 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our analysis also highlighted the potential of these LC-miRNAs to regulate the cell differentiation, proliferation, endocytosis and migration signaling logically required to cause an LC cell mainly through five canonical pathways (PI3K-Akt signaling pathway, pathways in cancer, MAPK signaling pathway, HTLV-I infection and focal adhesion).
|
24085243 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations have been associated with poor prognosis in patients with colorectal or lung cancer.
|
23532889 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To investigate the prevalence of phosphatidylinositol 3-kinase (PIK3CA) gene amplification in lung cancer, and to explore its prognostic value.
|
23335533 |
2013 |